Literature DB >> 7924752

Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation.

F J Farrell1, E B Keeffe, K M Man, J C Imperial, C O Esquivel.   

Abstract

Two patients with liver failure secondary to isoniazid hepatotoxicity were successfully treated with orthotopic liver transplantation. A 49-year-old man received isoniazid prophylaxis for a positive tuberculin test, and a 60-year-old woman was treated for active pulmonary tuberculosis with isoniazid, rifampin, and pyrazinamide. Both patients developed hepatic failure 4 and 1.5 months after initiation of antituberculous drug therapy, respectively. Liver transplantation was performed for progressive hepatic failure and was successful in both patients. The patient with active pulmonary tuberculosis was successfully treated with a modified antituberculous drug regimen while taking standard doses of immunosuppressive drugs after transplantation. In conclusion, liver transplantation is feasible and effective therapy for patients with isoniazid-induced hepatic failure, and active pulmonary tuberculosis may represent a relative rather than absolute contraindication to transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7924752     DOI: 10.1007/bf02090381

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Hepatitis cases in isoniazid treated groups and in a control group.

Authors:  N Riska
Journal:  Bull Int Union Tuberc       Date:  1976

2.  Isoniazid-associated hepatitis. Report of an outbreak.

Authors:  R A Garibaldi; R E Drusin; S H Ferebee; M B Gregg
Journal:  Am Rev Respir Dis       Date:  1972-09

3.  Isoniazid-associated hepatitis in 114 patients.

Authors:  M Black; J R Mitchell; H J Zimmerman; K G Ishak; G R Epler
Journal:  Gastroenterology       Date:  1975-08       Impact factor: 22.682

4.  Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.

Authors:  S R Salpeter
Journal:  West J Med       Date:  1993-11

5.  Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction.

Authors:  D Pessayre; M Bentata; C Degott; O Nouel; J P Miguet; B Rueff; J P Benhamou
Journal:  Gastroenterology       Date:  1977-02       Impact factor: 22.682

6.  Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.

Authors:  D E Kopanoff; D E Snider; G J Caras
Journal:  Am Rev Respir Dis       Date:  1978-06

7.  Risk factors for isoniazid (NIH)-induced liver dysfunction.

Authors:  D S Dickinson; W C Bailey; B I Hirschowitz; S J Soong; L Eidus; M M Hodgkin
Journal:  J Clin Gastroenterol       Date:  1981-09       Impact factor: 3.062

8.  Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent.

Authors:  S C Gilbert; G Klintmalm; A Menter; A Silverman
Journal:  Arch Intern Med       Date:  1990-04

9.  Early indicators of prognosis in fulminant hepatic failure.

Authors:  J G O'Grady; G J Alexander; K M Hayllar; R Williams
Journal:  Gastroenterology       Date:  1989-08       Impact factor: 22.682

10.  Liver transplantation in the management of fulminant hepatic failure.

Authors:  J C Emond; P P Aran; P F Whitington; C E Broelsch; A L Baker
Journal:  Gastroenterology       Date:  1989-06       Impact factor: 22.682

View more
  5 in total

1.  Liver and pancreatic injury induced by antituberculous therapy.

Authors:  M Markov; K Patel; A Raeesy; A Bant; D H Van Thiel; A Nadir
Journal:  Dig Dis Sci       Date:  2007-02-15       Impact factor: 3.199

2.  Successful living donor liver transplantation of fulminant liver failure due to isoniazid prophylaxis.

Authors:  Tuğrul Çakır; Cengiz Ara; Hacı Vural Soyer; Suleyman Koc
Journal:  BMJ Case Rep       Date:  2015-06-23

3.  Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system.

Authors:  David S Goldberg; Kimberly A Forde; Dena M Carbonari; James D Lewis; Kimberly B F Leidl; K Rajender Reddy; Kevin Haynes; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley; Vincent Lo Re
Journal:  Gastroenterology       Date:  2015-02-28       Impact factor: 22.682

Review 4.  Hepatotoxic effects of therapies for tuberculosis.

Authors:  Bahaa E Senousy; Sanaa I Belal; Peter V Draganov
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-31       Impact factor: 46.802

5.  Liver Transplantation in Antituberculosis Drugs-Induced Fulminant Hepatic Failure: A Case Report and Review of the Literature.

Authors:  Xiaoyan Li; Yujie Liu; Erhong Zhang; Qiong He; Yong-Bo Tang
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.